Blend CJC-1295 no DAC + Ipamorelin

What Is CJC-1295 (No DAC) + Ipamorelin?
CJC-1295 (No DAC) + Ipamorelin is an investigational fixed-combination peptide blend consisting of two mechanistically distinct but complementary growth hormone-releasing agents: CJC-1295 (No DAC) — a truncated, DAC-free tetradecapeptide analog of endogenous GHRH(1–29) — and Ipamorelin — a selective fifth-generation growth hormone secretagogue receptor (GHSR-1a) agonist derived from the Met-enkephalin scaffold. Together, the blend engages two independent neuroendocrine axes governing pulsatile GH release from anterior pituitary somatotrophs, and is actively studied in preclinical and early-phase research contexts for its combinatorial effects on the somatotropic axis.

Mechanism of Action
CJC-1295 (No DAC) binds to pituitary GHRH receptors (GHRHR), stimulating cAMP-dependent signaling cascades that promote synthesis and pulsatile secretion of endogenous growth hormone. Its short half-life (~30 minutes) preserves physiological GH pulse architecture. Ipamorelin acts via the GHSR-1a receptor in the hypothalamus and pituitary, mimicking ghrelin to amplify GH release through a distinct Gq/phospholipase C pathway, while demonstrating high receptor selectivity with minimal off-target activation of cortisol, prolactin, or ACTH secretory pathways. Co-administration produces additive or synergistic GH secretory amplitude by simultaneously activating both GHRHR and GHSR-1a pathways, leading to enhanced downstream IGF-1 hepatic synthesis — a key marker in somatotropic axis research.

Research & Clinical Trial Data
Current research utilization spans multiple investigational domains:

• Pulsatile GH Secretion Studies — In vitro and rodent model data demonstrate amplified GH pulse amplitude vs. either peptide alone
• IGF-1 Axis Modulation — Preclinical data indicate dose-dependent IGF-1 upregulation in hepatic tissue following combined administration
• Body Composition Research — Investigational rodent studies examining lean mass accretion and adipose reduction via somatotropic pathway activation
• Sleep Architecture Studies — Early research interest in GH secretory patterns during slow-wave sleep phases

Purity & Quality
Reference-grade material. Certificate of Analysis available per batch. Regulatory status: not approved by FDA or EMA for general therapeutic use as of current listing date.